SCHEMBL1170638

SCHEMBL1170638

O=S(=O)(O)CCCCN1CCN(CCO)CC1.O=S(=O)(O)CCN1CCN(CCO)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.37
APP P05067 1/20 0.34
CHRM2 P08172 1/20 0.34
HTR1A P08908 1/20 0.34
ADRA2A P08913 1/20 0.34
CHRM1 P11229 1/20 0.34
DRD2 P14416 1/20 0.34
ADRA2B P18089 1/20 0.34
ADRA2C P18825 1/20 0.34
DRD1 P21728 1/20 0.34
PTGS1 P23219 1/20 0.34
SLC6A2 P23975 1/20 0.34
HTR2A P28223 1/20 0.34
SLC6A4 P31645 1/20 0.34
ADRA1A P35348 1/20 0.34
HRH1 P35367 1/20 0.34
OPRM1 P35372 1/20 0.34
DRD3 P35462 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL118027 0.96 ALDH1A1 (0.45) ALDH1A1KDM4ESMN1; SMN2APPCHRM2
SCHEMBL207631 0.94 ALDH1A1 (0.44) ALDH1A1KDM4ESMN1; SMN2APPCHRM2
SCHEMBL98490 0.90 ALDH1A1 (0.47) ALDH1A1KDM4ESMN1; SMN2APPCHRM2
SCHEMBL9790 0.90 ALDH1A1 (0.45) ALDH1A1KDM4ECHRM2CHRM1KMT2A
SCHEMBL2229127 0.90 ALDH1A1 (0.45) ALDH1A1KDM4ECHRM2CHRM1KMT2A
SCHEMBL2417 0.90 ALDH1A1 (0.45) ALDH1A1KDM4ECHRM2CHRM1KMT2A
Water SCHEMBL29233228 0.89 ALDH1A1 (0.45) ALDH1A1KDM4ESMN1; SMN2APPCHRM2
SCHEMBL9493022 0.89 ALDH1A1 (0.45) ALDH1A1KDM4ESMN1; SMN2APPCHRM2
1,4-Butanediol SCHEMBL7566107 0.89 ALDH1A1 (0.41) ALDH1A1KDM4ESMN1; SMN2APPCHRM2
SCHEMBL3653844 0.88 ALDH1A1 (0.43) ALDH1A1KDM4ECHRM2CHRM1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110166202-A1 FORMOTEROL/STEROID BRONCHODILATING COMPOSITIONS AND METHODS OF USE THEREOF DEY, L.P. (US) 2011-07-07 US disclosed
US-20110135730-A1 Oral Formulations of Glycyl-2-Methylprolyl-Glutamate NEUREN PHARMACEUTICALS LIMITED (AU) 2011-06-09 US disclosed
US-7887839-B2 microemulsions, water in oil emulsion, continuous hydrophobic phase including oil, surfactant; for treatment of neurodegenerative disorders; tablets; pharmacokinetics, bioavailability NEUREN PHARMACEUTICALS LTD. (NZ) 2011-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166202-A1 FORMOTEROL/STEROID BRONCHODILATING COMPOSITIONS AND METHODS OF USE THEREOF ADRB2, CYP11B2, ADRB3 ALDH1A1 2688/4885KDM4E 4789/4885SMN1; SMN2 1837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.